authority to conduct hearings and to issue decisions with respect to cases involving provider participation and termination under sections 1866(b)(2) and 1866(h), and 1910(b) of the Social Security Act (the Act); cases involving parallel procedures applicable to conditions for coverage for practitioners and suppliers under the Act, as described in 42 CFR 498.3(b); cases involving payment for cardiac pacemaker implantation under section 1862(h)(4) of the Act; cases involving conditions for coverage for organ procurement organizations under section 1138(b) of the Act; cases involving termination of coverage, or alternative sanctions, imposed on a supplier of end stage renal disease services for failure to participate in network activities under section 1881(c)(3) of the Act; and cases involving suspension, revocation, or limitation of laboratory licenses under section 353(i)(1) of the Public Health Service Act; (42 U.S.C. 1395cc (b)(2) and (h); 1396i(b); 1396i(c); 1395y(h)(4); 1320b–8(b); 1395rr(c)(3); and 42 U.S.C. 263a(i)(1)).

I have also delegated to any and all Administrative Law Judges in, assigned to, or detailed to, the Departmental Appeals Board, my authority to conduct hearings and to issue decisions with respect to cases involving enforcement actions, including, if applicable, civil money penalties and other intermediate sanctions, under sections 1819(h)(2) (A) and (B); 1846; 1866(i); 1881(g); 1891(e)(1), (2) and (3) and (f)(2)(A); 1919(h)(3)(A), (B), and (C) of the Act; and section 353(h) of the Public Health Service Act; (42 U.S.C. 1395i–3(h)(2) (A) and (B); 1395w–2; 1395cc(i); 1395rr(g); 1395bbb(e)(1), (2), and (3) and (f)(2)(A); 1396r(h)(3)(A), (B), and (C); and 42 U.S.C. 263a(h)).

This delegated authority to conduct hearings and issue decisions is limited to those cases in which the appealing party is entitled, either by statute or regulation, to request a hearing by an Administrative Law Judge. This delegation includes, but is not limited to, the authority to administer oaths and affirmations, to subpoena witnesses and documents, to examine witnesses, to exclude or receive and give appropriate weight to materials and testimony offered as evidence, to make findings of fact and conclusions of law, and to determine the civil remedies to be imposed, which determinations will be final unless reviewed by the Departmental Appeals Board.

This delegation, which supersedes all previous delegations of authority to conduct hearings and render decisions based on the above-referenced authorities on cases brought by the Health Care Financing Administration, is effective immediately, except that Administrative Law Judges in the Social Security Administration's Office of Hearings and Appeals shall continue to have the authority to conduct hearings and issue decisions in cases currently pending before them.

Dated: October 13, 1993.

Donna E. Shalala,

Secretary.

[FR Doc. 93–26716 Filed 10–28–93; 8:45 am]

BILLING CODE 4120–03–M

Statement of Organization, Functions, and Delegations of Authority

Notice is hereby given that I have delegated to the Chair and Members of the Departmental Appeals Board my authority to make final decisions on review of, or to decline to review, decisions of Administrative Law Judges involving provider participation and termination under sections 1866(b)(2) and 1866(h), and 1910(b) of the Social Security Act (the Act); decisions involving parallel procedures applicable to conditions for coverage for practitioners and suppliers under the Act, as described in 42 CFR 498.3(b); decisions involving payment for cardiac pacemaker implantation under section 1862(h)(4) of the Act; decisions involving conditions for coverage for organ procurement organizations under section 1138(b) of the Act; decisions involving termination of coverage, or alternative sanctions, imposed on a supplier of end stage renal disease services for failure to participate in network activities under section 1881(c)(3) of the Act; and decisions involving suspension, revocation, or limitation of laboratory licenses under section 353(i)(1) of the Public Health Service Act; (42 U.S.C. 1395cc (b)(2) and (h); 1396i(b); 1396i(c); 1395y(h)(4); 1320b–8(b); 1395rr(c)(3); and 42 U.S.C. 263a(i)(1)).

I have also delegated to the Chair and Members of the Departmental Appeals Board my authority to make final decisions on review of, or to decline to review, decisions of Administrative Law Judges involving enforcement actions, including, if applicable, civil money penalties and other intermediate sanctions, under sections 1819(h)(2) (A) and (B); 1846; 1866(i); 1881(g); 1891(e)(1), (2) (3) and (f)(2)(A); 1919(h)(3) (A), (B), and (C) of the Act; and section 353(h) of the Public Health Service Act; (42 USC 1395i–3(h)(2) (A) and (B); 1395w–2; 1395cc(i); 1395rr(g); 1395bbb(e) (1), (2), and (3) and (f)(2)(A); 1396r(h)(3) (A), (B), and (C); and 42 U.S.C. 263a(h)).

The delegation includes, but is not limited to, the authority to administer oaths and affirmations, to subpoena witnesses and documents, to examine witnesses, to exclude or receive and give appropriate weight to materials and testimony offered as evidence, to make findings of fact and conclusions of law, and to determine the civil remedies to be imposed.

This delegation, which supersedes all previous delegations of authority to review decisions by Administrative Law Judges on the above-referenced authorities on cases brought by the Health Care Financing Administration, is effective immediately, except that the Social Security Administration, Office of Hearings and Appeals, Appeals Council shall continue to have the authority to review, or to decline to review decisions in cases currently pending before it.

Dated: October 13, 1993.

Donna E. Shalala,

Secretary.

[FR Doc. 93–26717 Filed 10–28–93; 8:45 am]

BILLING CODE 4120–03–M

Administration for Children and Families

Third Meeting of the Advisory Committee on Head Start; Quality and Expansion

AGENCY: Administration for Children and Families, DHHS.

ACTION: Correction on notice of meeting.

SUMMARY: On October 20 a notice was published (58 FR 54156), announcing that the Head Start Advisory Committee on Head Start Quality and Expansion will hold its third meeting on Tuesday, November 2, 1993. The address of the meeting has changed. The correct address for the meeting is the: Hyatt Regency Capitol Hill, 400 New Jersey Avenue, NW., Washington, DC

The meeting will be held from 9 a.m. to 4 p.m.

FOR FURTHER INFORMATION CONTACT:

David Siegel, 7th Floor, Aerospace Building, 370 L'Enfant Promenade, SW., Washington, DC 20447, (202) 401–9215.

Dated: October 27, 1993.

Howard Rolston,

Director, Office of Policy and Evaluation.

[FR Doc. 93–26829 Filed 10–27–93; 1:58 pm]

BILLING CODE 4184–01–M

Centers for Disease Control and Prevention

Fernald Dosimetry Reconstruction Project Workshop: Public Meeting

The National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC), and the Radiological Assessments Corporation announce the following meeting.

Name: Fernald Dosimetry Reconstruction Project Workshop.

Time and Date: 7 p.m.–9 p.m., November 30, 1993.

Place: Sheraton Springdale Hotel, 11911 Sheraton Lane, Springdale, Ohio 45246.

Status: Open to the public for observation and comment, limited only by space available. The meeting room accommodates approximately 75–100 people.

Purpose: Under the Memorandum of Understanding with the Department of Energy (DOE), the Department of Health and Human Services has been given the responsibility and resources for conducting analytic epidemiologic investigations of residents of communities in the vicinity of DOE facilities and other persons potentially exposed to radiation or to potential hazards from non-nuclear energy production and use. The purpose of the workshop is to discuss findings of the final Task 2 and 3 Report, Radionuclide Source Terms and Uncertainties For All Years, that describes the releases of materials from the Feeds Material Production Center for all years of operation.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Paul Renard, Radiation Studies Branch, Division of Environmental Hazards and Health Effects, NCEH, CDC, 4770 Buford Highway, NE, (F–35), Atlanta, Georgia 30341–3724, telephone 404/488–7040.

Dated: October 25, 1993.

Elvin Hilyer,

Associate Director for Policy Coordination, Centers for Disease Control and Prevention (CDC).

[FR Doc. 93–26650 Filed 10–28–93; 8:45 am]

BILLING CODE 4160–18–M

Food and Drug Administration

[Docket No. 93F–0360]

Henkel Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Henkel Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of pentaerythritol mixed esters of C_{16-18} fatty acids as a dispersant for titanium dioxide in polyethylene, polypropylene, and polystyrene intended for contact with food.

DATES: Written comments on the petitioner's environmental assessment by November 29, 1993.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Andrew J. Zajac, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–254–9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 3B4400) has been filed by Henkel Corp., 300 Brookside Ave., Ambler, PA 19002–3498. The petition proposes to amend the food additive regulations to provide for the safe use of pentaerythritol mixed esters of C_{16-18} fatty acids as a dispersant for titanium dioxide in polyethylene, polypropylene, and polystyrene intended for contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act 40 CFR 1501.4(b), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before November 29, 1993, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: October 20, 1993.

Janice F. Oliver,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 93–26612 Filed 10–28–93; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 93F–0361]

Hoechst Celanese Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Hoechst Celanese Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 4-[[5-[[[4-(aminocarbonyl)phenyl] amino]carbonyl]-2-methoxyphenyl]azo]- *N*-(5-chloro-2,4-dimethoxyphenyl)-3- hydroxy-2-naphthalene carboxamide (C. I. Pigment Red 187) as a colorant for all polymers intended for use in contact with food.

DATES: Written comments on the petitioner's environmental assessment by November 29, 1993.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Vir Anand, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–254–9500.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 3B4402) has been filed by Hoechst Celanese Corp., Colorants Division, 500 Washington St., Coventry, RI 02186. The petition proposes to amend the food additive regulations in § 178.3297 *Colorants for polymers* (21 CFR 178.3297) to provide for the safe use of 4-[[5-[[[4-(aminocarbonyl) phenyl]amino] carbonyl]-2-methoxy phenyl]azo]-*N*- (5-chloro-2,4-dimethoxy phenyl)-3- hydroxy-2-naphthalene carboxamide (C. I. Pigment Red 187) as a colorant for all polymers intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition

that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before November 29, 1993, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: October 20, 1993.

Janice F. Oliver,

Acting Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 93–26611 Filed 10–28–93; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). This notice also summarizes the procedures for the meeting and methods by which interested persons may participate in open public hearings before FDA's advisory committees.

MEETING: The following advisory committee meeting is announced:

Science Advisory Board to the National Center for Toxicological Research

Date, time, and place. November 16 and 17, 1993, 9 a.m., Bldg. 12, conference rm., National Center for Toxicological Research (NCTR), Jefferson, AR.

Type of meeting and contact person. Open committee discussion, November 16, 1993, 9 a.m. to 4:30 p.m.; open committee discussion, November 17, 1993, 9 a.m. to 1:30 p.m.; open public hearing, 1:30 p.m. to 2:30 p.m., unless public participation does not last that long; closed board deliberations, 2:30 p.m. to 3:30 p.m.; Ronald F. Coene, NCTR (HFT–10), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3155.

General function of the board. The board advises on establishment and implementation of a research program that will assist the Commissioner of Food and Drugs to fulfill regulatory responsibilities.

Agenda—Open public hearing. Interested persons may present data, information, or views, orally or in writing, on issues pending before the board. Those desiring to make a formal presentation should notify the contact person before November 8, 1993, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time required to make their comments.

Agenda—Open board discussion. The board will conduct a review of its subcommittee site visit draft reports on two research programs of the center: (1) Nutritional Modulation of Risk and Toxicity Program, and (2) Applied and Environmental Microbiology Program. The board will engage in discussions on these reports and come to a final conclusion on the recommendations to be made to the Director, NCTR, concerning these center programs. A progress report on the recommendations of three previously reviewed research programs of the center: (1) Quantitative Risk Assessment, (2) Developmental Toxicology, and (3) Neurotoxicology will also be presented. A final agenda will be available on November 10, 1993, by contacting the contact person.

Agenda—Closed board deliberations. The board will discuss information of a personal nature, where disclosure would constitute a clearly unwarranted invasion of personal privacy relative to the intramural scientific program (5 U.S.C. 552b(c)(6)). This portion of the meeting will be closed to discuss this information.

The Commissioner approves the scheduling of meetings at locations outside of the Washington, DC, area on the basis of the criteria of 21 CFR 14.22 of FDA's regulations relating to public advisory committees.

Each public advisory committee meeting listed above may have as many as four separable portions: (1) An open public hearing, (2) an open committee discussion, (3) a closed presentation of data, and (4) a closed committee deliberation. Every advisory committee meeting shall have an open public hearing portion. Whether or not it also includes any of the other three portions will depend upon the specific meeting involved. The dates and times reserved for the separate portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this **Federal Register** notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr.,

Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

The Commissioner has determined for the reasons stated that those portions of the advisory committee meetings so designated in this notice shall be closed. The Federal Advisory Committee Act (FACA) (5 U.S.C. app. 2, 10(d)), permits such closed advisory committee meetings in certain circumstances. Those portions of a meeting designated as closed, however, shall be closed for the shortest possible time, consistent with the intent of the cited statutes.

The FACA, as amended, provides that a portion of a meeting may be closed where the matter for discussion involves a trade secret; commercial or financial information that is privileged or confidential; information of a personal nature, disclosure of which would be a clearly unwarranted invasion of personal privacy; investigatory files compiled for law enforcement purposes; information the premature disclosure of which would be likely to significantly frustrate implementation of a proposed agency action; and information in certain other instances not generally relevant to FDA matters.

Examples of portions of FDA advisory committee meetings that ordinarily may be closed, where necessary and in accordance with FACA criteria, include the review, discussion, and evaluation of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, notably deliberative session to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: October 25, 1993.

Jane E. Henney,

Deputy Commissioner for Operations.

[FR Doc. 93–26662 Filed 10–28–93; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Cancer Institute; Meeting of the Board of Scientific Counselors, Division of Cancer Biology, Diagnosis, and Centers

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Board of Scientific Counselors, Division of Cancer Biology, Diagnosis, and Centers, National Cancer Institute, November 30, 1993. The meeting will be held in Building 31C, Conference Room 6, National Institutes of Health, Bethesda, Maryland 20892.

The entire meeting will be open to the public from 8:30 a.m. until adjournment for program review and concept review of proposed research projects. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. Sandra Carter at 301–496–4345 in advance of the meeting.

The Committee Management Office, National Cancer Institute, Executive Plaza North, Room 630, 6130 Executive Boulevard, Rockville, Maryland 20892 (301–496–5708) will provide summary minutes of the meeting and roster of committee members.

Dr. Ihor J. Masnyk, Deputy Director, Division of Cancer Biology, Diagnosis, and Centers, National Cancer Institute, Building 31, room 3A03, National Institutes of Health, Bethesda, Maryland 20892 (301–496–3251) will provide substantive program information.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)

Dated: October 21, 1993.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 93–26615 Filed 10–28–93; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Alcohol Abuse and Alcoholism, Meeting of the Board of Scientific Counselors

Pursuant to Public Law 92–463, notice is hereby given of the meeting of the Board of Scientific Counselors, National Institute on Alcohol Abuse and Alcoholism, November 23, 1993, NIH Campus, Building 49, Conference Room A, 9000 Rockville Pike, Bethesda, MD 20892.

This meeting will be open to the public from 7:30 a.m. to 8 a.m. on November 23 for a report on recent administrative developments. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Diana Widner, Office of Scientific Affairs, NIAAA, at (301) 443–4375.

In accordance with the provisions set forth in section 552b(c)(6), Title 5, U.S.C. and section 10(d) of Public Law 92–463, the meeting will be closed to the public from 8 a.m. on November 23 to adjournment on November 23 for the review, discussion, and evaluation of intramural research programs and projects conducted by the National Institute on Alcohol Abuse and Alcoholism, including consideration of personnel qualifications and performance, and the productivity of individual staff scientists, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Summaries of the meeting and the roster of committee members may be obtained from: Ms. Diana Widner, NIAAA Committee Management Officer, National Institute on Alcohol Abuse and Alcoholism, Parklawn Building, Room 16C–20, 5600 Fishers Lane, Rockville, MD 20857, Telephone: 301/443–4375.

Substantive program information may be obtained from: Theodore Colburn, Ph.D., room 1B58, Building 31, Telephone (301) 402–1226.

Dated: October 22, 1993.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 93–26614 Filed 10–28–93; 8:45 am]

BILLING CODE 4140–01–M